

# THE PROBLEM: ALZHEIMER'S DISEASE

Alzheimer's disease is :

- the most common form of dementia of the elderly
- gets progressively worse and there is no remission
- is the 6th leading cause of death in the USA
- affecting more than 5 million Americans / 30 million worldwide
- is the only cause of death among the top 10 in America that cannot be prevented, cured or even slowed.

A black and white photograph showing a silhouette of a person walking away from the viewer down a brightly lit hallway. The person is walking towards a bright light at the end of the hallway. In the foreground, a wheelchair is visible, suggesting the person is using it. The overall mood is somber and evocative.

**IT IS  
DEVASTATING**

**Alzheimer's Disease is associated with:**

- **memory loss**
- **confusion**
- **aphasia**
- **loss of executive function**
- **personality change**
- **occasionally with paranoia, aggression and hallucinations**



# FINDING A CURE: WHAT WE KNOW

The cause of Alzheimer's Disease is unknown but it is characterized by plaques and tangles in the brain, found near/ within degenerating neurons. These lesions can now be detected by appropriate brain PET scans in live patients.

Aiming to remove or reduce those lesions is a strategy employed by drug developers, but so far all efforts failed, either because of safety or efficacy issues

# NEUROTEZ: A PROMISING SOLUTION

Many studies in disease models have shown that leptin is neuroprotective, improves cognition and is accompanied by a decrease in levels of both phospho-tau/tau and beta amyloid ( $A\beta$ ), the factors linked to the lesions in Alzheimer's disease pathology.

Because leptin is a naturally occurring hormone and is at low levels in Alzheimer's patients, leptin replacement therapy represents a relatively de-risked multi-functional therapeutic approach.



## Management team:


Nikolaos Tezapsidis, PhD  
J Wes Ashford, MD, PhD  
George Perry, PhD  
Eugene Oliva, MBA  
Jane Johnston, PhD  
Steven Greco, PhD

## Directors:

Nikolaos Tezapsidis, PhD  
George Perry, PhD  
Eugene Oliva, MBA  
James Harris, MBA  
Jeff Swarz, PhD  
Haro Hartounian, PhD  
J Wes Ashford, MD, PhD

## Advisors:

Arthur Klausner, MBA  
Lex Van der Ploeg, PhD  
Steve Jacobsen, PhD  
Gilbert Block, MD, PhD  
Lawrence Friedhoff, MD, PhD  
Daniel Van Kammen, MD, PhD  
Kent Iverson, BS



## Contact:

Nikolaos Tezapsidis  
President & CEO  
Neurotez, Inc.  
991 Highway 22, Suite 200A,  
Bridgewater, NJ 08807, USA  
Tel:+1-908-998-1340  
Fax: +1-908-864-8957  
[ntezapsidis@neurotez.com](mailto:ntezapsidis@neurotez.com)



**Neurotez**